KDR and cancer: VEGFR2 is a mainstay in the inhibition (cancer treatment) or promotion (ischemic disorders) of angiogenesis, and the VEGF/VEGFR2 is the major signaling pathway targeted by (poly)phenols (Tables S1 and S2).